Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Adjuvant chemotherapy for patients with completely resected stage II and select stage III
NSCLC is considered standard therapy. At least three large, prospective randomized trials
have proven the benefit of adjuvant chemotherapy in improving survival in these patients
(with a magnitude of benefit ranging from 4-12%). However, in patients who are not
considered to be candidates for up-front complete resection, preoperative therapy may be
indicated. Many of these patients will subsequently be eligible for resection (bimodality
therapy). The rationale for this multicenter, Phase II trial is to examine the impact of
carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage
IB (>4.0 cm), II, and select stage III NSCLC. This trial will be conducted by the Sarah
Cannon Research Institute Oncology Research Consortium. If this novel regimen proves to be
safe and active in this setting, this would provide rationale for further investigation in a
larger, prospective, randomized setting.